The mechanism of action for Invega Sustenna involves the sustained release of paliperidone palmitate, an atypical antipsychotic [1]. Once administered intramuscularly, paliperidone palmitate forms a depot that slowly dissolves, releasing paliperidone into the bloodstream over time [1][2].
How Does Paliperidone Work?
Paliperidone acts as a serotonin-dopamine antagonist [1]. It binds to dopamine D2 and serotonin 5-HT2A receptors in the brain [1][3]. By blocking these receptors, paliperidone helps to regulate neurotransmitter activity, which is believed to be involved in the symptoms of schizophrenia [1][3].
What is the Difference Between Invega and Invega Sustenna?
Invega (paliperidone immediate-release tablets) is taken orally once daily, while Invega Sustenna (paliperidone palmitate extended-release injectable suspension) is an intramuscular injection administered monthly [4]. The sustained-release formulation of Invega Sustenna allows for less frequent dosing and provides consistent plasma concentrations of paliperidone [2].
How Long Does Invega Sustenna Last?
Invega Sustenna is designed to provide therapeutic levels of paliperidone for one month following intramuscular injection [2].
What Are the Side Effects of Invega Sustenna?
Common side effects reported with Invega Sustenna include movement disorders (akathisia, extrapyramidal symptoms), insomnia, headache, and weight gain [1]. More serious potential side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes [1].
When is Paliperidone Palmitate Patent Expiry?
Information on specific patent expiry dates for paliperidone palmitate and related formulations can be found on DrugPatentWatch.com [5].
Who Makes Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [4].
Sources
1. https://www.ncbi.nlm.nih.gov/books/NBK564369/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710448/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065548/
4. https://www.janssen.com/
5. https://drugpatentwatch.com/